1. Home
  2. TMDX vs QFIN Comparison

TMDX vs QFIN Comparison

Compare TMDX & QFIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TMDX
  • QFIN
  • Stock Information
  • Founded
  • TMDX 1998
  • QFIN 2016
  • Country
  • TMDX United States
  • QFIN China
  • Employees
  • TMDX N/A
  • QFIN N/A
  • Industry
  • TMDX Biotechnology: Electromedical & Electrotherapeutic Apparatus
  • QFIN Finance: Consumer Services
  • Sector
  • TMDX Health Care
  • QFIN Finance
  • Exchange
  • TMDX Nasdaq
  • QFIN Nasdaq
  • Market Cap
  • TMDX 4.0B
  • QFIN 3.1B
  • IPO Year
  • TMDX 2019
  • QFIN 2018
  • Fundamental
  • Price
  • TMDX $115.50
  • QFIN $23.40
  • Analyst Decision
  • TMDX Buy
  • QFIN Strong Buy
  • Analyst Count
  • TMDX 11
  • QFIN 2
  • Target Price
  • TMDX $130.73
  • QFIN $45.10
  • AVG Volume (30 Days)
  • TMDX 1.0M
  • QFIN 2.2M
  • Earning Date
  • TMDX 10-29-2025
  • QFIN 11-18-2025
  • Dividend Yield
  • TMDX N/A
  • QFIN 6.53%
  • EPS Growth
  • TMDX 170.70
  • QFIN 68.82
  • EPS
  • TMDX 2.54
  • QFIN 7.06
  • Revenue
  • TMDX $566,354,000.00
  • QFIN $2,618,582,596.00
  • Revenue This Year
  • TMDX $38.84
  • QFIN $17.10
  • Revenue Next Year
  • TMDX $20.46
  • QFIN $6.28
  • P/E Ratio
  • TMDX $45.56
  • QFIN $3.29
  • Revenue Growth
  • TMDX 41.20
  • QFIN 9.77
  • 52 Week Low
  • TMDX $55.00
  • QFIN $20.45
  • 52 Week High
  • TMDX $145.50
  • QFIN $48.94
  • Technical
  • Relative Strength Index (RSI)
  • TMDX 42.14
  • QFIN 43.19
  • Support Level
  • TMDX $115.21
  • QFIN $21.59
  • Resistance Level
  • TMDX $125.57
  • QFIN $23.79
  • Average True Range (ATR)
  • TMDX 7.47
  • QFIN 1.38
  • MACD
  • TMDX -1.51
  • QFIN 0.24
  • Stochastic Oscillator
  • TMDX 4.92
  • QFIN 41.07

About TMDX TransMedics Group Inc.

TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The Company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.

About QFIN Qifu Technology Inc.

Qfin Holdings Inc Formerly Qifu Technology Inc is a Credit-Tech platform in China. It provides credit services more accessible and personalized to consumers and SMEs through Credit-Tech services to financial institutions, whereby it deploys its technology solutions to help financial institutions identify the diversified needs of consumers and SMEs, effectively access prospective borrowers that are creditworthy through multi-channels, enhance credit assessment on prospective borrowers, and manage credit risks and improve collection strategies and efficiency, among others.

Share on Social Networks: